Carfilzomib, iberdomide, and dexamethasone (KID) therapy before autologous transplant showed a 98% response rate in multiple #myeloma, with 31% achieving complete or stringent complete response.

📰 Read more from a study led by @BiranNoa of @HMHNewJersey @JTCancerCenter.

➡️ buff.ly/qJsSWMn

📍 We’re onsite today at @JTCancerCenter @HMHNewJersey!

From breast to colorectal and gynecologic cancers, we’re sitting down with leading experts to discuss the latest in cancer care. Stay tuned for new interviews coming soon! 🎥

#Oncology #CancerCare #CancerResearch

📰 GLP-1s are generating significant buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression. #bcsm #oncology

Read insights from Deena Graham, MD, of @JTCancerCenter and @HMHNewJersey here: onclive.com/view/a-new-pla…

🎥On this video podcast episode of #OncLiveOnAir, @BiranNoa of @JTCancerCenter broke down key multiple myeloma data shared at the 2026 @ASCO Annual Meeting.

Watch here ➡️: onclive.com/view/unpacking…

#mmsm #oncology

@JTCancerCenter opening first-in-human trial of ML261, a potency-enhanced anti-DLL3 CAR T therapy, in relapsed SCLC and NEC. Advancing cellular therapies in solids. @ADesaiMD @salmanpunekar #LCSM #SCLC sprou.tt/1MBEdt2E1rS

👀 Robotic surgery, transvesical approaches, and the single-port era, were all topics covered by @RoboticsUrology of @JTCancerCenter in his commentary on paradigm shifts in minimally invasive surgeries.

Full details here 🤖: hubs.li/Q040d3MB0

#pcsm #oncology

"[Patients] with #LungCancer are often met with accusations, said @drCarterBawa [of] @HMHNewJersey. The first question that anybody asks is, 'Did you smoke?' she said." @nytimes highlighting @drCarterBawa's incredible #LungCancer stigma work! Read more 👇
nytimes.com/2026/01/14/wel…

🩺 The Three Pillars of #PancreasCancer Treatment

Dr. Benjamin Jon Golas, of @JTCancerCenter, breaks down how surgery, chemo, and radiation form the foundation of curative-intent therapy for pancreas cancer.

Learn more and wathc the whole video here! hubs.li/Q03_0mQK0

Thanks to @DavidSSiegelMD of @JTCancerCenter and @HackensackUMC for stopping by at #ASH25 to discuss real-world data with talquetamab or elranatamab with pomalidomide in myeloma! See our site for more from the meeting. @ASH_hematology #mmsm #hematology
onclive.com/conference/ash

WATCH: Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma. @LoriLeslieMD @JTCancerCenter @HackensackUMC @ASH_hematology #ASH25 #lymsm #hematology
onclive.com/view/dr-leslie…

A huge thanks to @LoriLeslieMD of @JTCancerCenter who stopped by for an interview to discuss data from the phase 1b/2 EPCORE NHL-2 trial! Check back on hubs.li/Q03Xm7WY0 for highlights from the interview. @ASH_hematology #ASH25

Another conversation done with @PoojaPhullHatti @HMHNewJersey this time about gut microbiome shifts and butyrate producers connection to PFS in multiple myeloma patients! 👀

Watch out for more insight in her interview with hubs.li/Q03XbzbW0!
@ASH_hematology #ASH2025 #mmsm

CONGRESS | #ASH25 | PRESENTATION
Lori Leslie shares 3-year results from the phase Ib/II EPCORE NHL-2 trial, of 1L epcoritamab with rituximab + lenalidomide (Arm 6; n = 41) and epcoritamab maintenance monotherapy following SOC (Arm 7; n = 19), in patients with FL.

The ORR with + lenalidomide in Arm 6 was 95% and the CR rate was 88%. In Arm 7, 100% of patients with PR from last line of therapy (n = 8) achieved CR after a median of 2.8 months (range, 2.5–5.7). No new safety signals were observed in either arm; the majority of TEAEs were infectious in nature.
Data indicate favorable safety and efficacy of epcoritamab, in combination with rituximab in 1L and as maintenance monotherapy, in FL.

Follow our live feed for more updates: loom.ly/POS6cqk
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedEd #MedicalCongress
@LoriLeslieMD @HMHNewJersey

📺 Watch “Your New Jersey” Saturdays at 6 AM and Sundays at 8 AM on MeTV WJLP New Jersey/New York!

This weekend:
1️⃣ Lindsay Colameo Peragallo, Founder of Beauty Holiday and & Lauren Encarnacion, Project Coordinator at @HMHNewJersey John Theurer Cancer Center, sharing how their collare packages to patients undergoing treatment💄


2️⃣ Lauren D’Amelio, Founder of D’Amelio Cosmetics & Nicolette Dalessandro, Celebrity Makeup Artist discuss empowering artists, running high-profile events, and giving back through their work✨

For more information, visit UpdateNewJersey.com

#TV #Television #YourNewJersey #UpdateNewJersey #MeTV #WJLP #NewJersey #NJ #Watch #Local #Community #GivingBack #BeautyIndustry #SelfCare #Inspiration #LocalLife

Eating well during cancer treatment can be challenging.
In this interview with CURE, registered dietitian Kanisha Parikh from John Theurer Cancer Center shares practical tips for maintaining nutrition when eating becomes difficult.
curetoday.com/view/eating-ti…

@HMHNewJersey

🥗 Safe food matters, especially for immunocompromised patients with #Cancer!

Dietitian Heather Ann Yonker, of @JTCancerCenter, shares step-by-step tips for handling, cooking, and storing poultry safely at home.

Learn more from CURE! 👇 hubs.li/Q03LK4Nr0

🥗 #FoodSafety is essential for everyone, especially patients w/ cancer & w/ weakened immune systems. @JTCancerCenter #CancerCare

“Food safety is everyone's business, & we all need to consider this in our daily practice,” Heather Ann Yonker emphasizes.
hubs.li/Q03KVjrz0

👨‍⚕️ A Pediatric Nurse Shares Her #BreastCancer Journey

Amanda Davis, a pediatric emergency nurse at @JTCancerCenter and mother, navigated her breast cancer diagnosis while caring for others.

Read more about her journey and insights here: hubs.li/Q03KHm2s0

Former fighter pilot Mark Daniels credits oncologist Andre Goy, MD, MS, and CAR T-cell therapy at @JTCancerCenter with saving his life from aggressive B-cell #lymphoma. ow.ly/3uph50WRveU

As a rare and understudied tumor type, #AppendicealCancer has seen an increase in its incidence since 2010, though the reason remains unclear. @LigrestiRosario @HMHNewJersey #AppendixCancerAwarenessMonth
Read here:
onclive.com/view/rising-in…